Based in San Antonio, Texas, OncoVista was incorporated in 2004 and utilizes state-of-the-art drug discovery technologies, innovative clinical development and registration strategies as well as emerging technologies to bring to market new, safe and highly effective anti-cancer drugs.

	2004	Company founded based on two key platform technologies
	2005	Acquired majority share in AdnaGen AG
	2006	Merged with Aengus Pharmaceuticals
		Acquired a Phase I/II clinical candidate
	2007	Became publicly-traded
		In-licensed a Phase II clinical candidate
	2008	Initiated Phase I/II clinical trial for leukemia at two US sites
		Launched CLIA lab capability in the US
		Increase sales of AdnaGen diagnostic kits in Europe
		Increased ownership of AdnaGen AG to more than 95%